M22-716 is a Phase 1, FIH, open-label, dose escalation, dose expansion, biomarker/pharmacodynamic (PD) study of ABBV-319 in participants with relapsed or refractory (R/R) B-cell malignancies.

To evaluate the safety, tolerability, MTD and the RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available.

This is an open-label, Phase 1/2, dose escalation, dose expansion and cohort expansion study to evaluate the safety, tolerability, PK, PD and clinical activity of FMC-376 in participants with locally advanced unresectable or metastatic solid tumors which harbor KRAS G12C mutation.

The first-in-human clinical study will be a Phase 1, multicenter, open-label, multiple dose, two-part study of LNCB74 that will include Dose Escalation (Part 1) and Dose Expansion/Optimization (Part 2). The objectives of this study will be to determine the safety and tolerability, define the maximum tolerated dose (MTD), maximal administered dose (MAD) and/or the recommended Phase 2 dose (RP2D), and to assess the preliminary efficacy of LNCB74 in participants with advanced or metastatic solid tumors.

Part 1 (dose escalation): to evaluate the safety and tolerability of SIM0505 and determine the maximum tolerated dose (MTD)

This is a multi-center, open-label, Phase I/II clinical study of YL205. This study includes: Phase I dose escalation and backfill, and Phase II dose expansion. It is to evaluate the safety and tolerability of YL205 in patients with advanced solid tumors who have experienced treatment failure of existing standard therapies, have no standard treatment options, are currently not suitable for standard treatments, or cannot benefit from other approved therapies in dose escalation, and will backfill patients in certain tolerable dose levels to further evaluate the efficacy and safety of YL205.

To evaluate the safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors. To determine the recommended dose(s) and schedule(s) of IM-1021 for further development.

This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone.